The role of epigenetics in the regulation of apoptosis in myelodysplastic syndromes and acute myeloid leukemia

Critical Reviews in Oncology/Hematology

Volumn 90, Issue 1, 2014, Pages 1-16

  Karlic, Heidrun ^a,b   Herrmann, Harald ^a   Varga, Franz ^b   Thaler, Roman ^b   Reitermaier, Rene ^a,b   Spitzer, Silvia ^b   Ghanim, Viviane ^c   Blatt, Katharina ^a,c   Sperr, Wolfgang R ^a,c   Valent, Peter ^a,c   Pfeilstöcker, Michael ^a,b  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b HANUSCH HOSPITAL   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Apoptosis; Autophagy; Demethylating drugs; Epigenetics

Indexed keywords

AZATHIOPRINE; CD34 ANTIGEN; CD38 ANTIGEN; DICHLOROACETIC ACID; FAS ANTIGEN; PROTEIN DAPK1; PROTEIN SERINE THREONINE KINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; APOPTOSIS; AUTOPHAGY; CANCER RESISTANCE; DEMETHYLATION; EPIGENETICS; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC ASSOCIATION; HIGH RISK PATIENT; HUMAN; MYELODYSPLASTIC SYNDROME; NONHUMAN; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN METHYLATION; PROTEIN TARGETING; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; STEM CELL; TUMOR SUPPRESSOR GENE;

APOPTOSIS; AUTOPHAGY; DEMETHYLATING DRUGS; EPIGENETICS;

ANIMALS; APOPTOSIS; EPIGENESIS, GENETIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; PROMOTER REGIONS, GENETIC;

EID: 84895506739     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.10.003     Document Type: Review

References (155)

1. Pang W.W., Pluvinage J.V., Price E.A., et al. Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. Proc Natl Acad Sci U S A 2013, 110:3011-3016.
2. Valent P., Horny H.P., Bennett J.M., et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007, 31:727-736.
3. Pfeilstocker M., Karlic H., Nosslinger T., et al. Myelodysplastic syndromes, aging, and age: correlations, common mechanisms, and clinical implications. Leuk Lymphoma 2007, 48:1900-1909.
4. Issa J.P. The myelodysplastic syndrome as a prototypical epigenetic disease. Blood 2013, 121:3811-3817.
5. Greenberg P.L. Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. Leuk Res 1998, 22:1123-1136.
6. Bouscary D., De Vos J., Guesnu M., et al. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia 1997, 11:839-845.
7. Aul C., Bowen D.T., Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica 1998, 83:71-86.
8. Bouscary D., Chen Y.L., Guesnu M., et al. Activity of the caspase-3/CPP32 enzyme is increased in early stage myelodysplastic syndromes with excessive apoptosis, but caspase inhibition does not enhance colony formation in vitro. Exp Hematol 2000, 28:784-791.
9. Claessens Y.E., Bouscary D., Dupont J.M., et al. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood 2002, 99:1594-1601.
10. Corey S.J., Minden M.D., Barber D.L., et al. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer 2007, 7:118-129.
11. Gersuk G.M., Lee J.W., Beckham C.A., et al. Fas (CD95) receptor and Fas-ligand expression in bone marrow cells from patients with myelodysplastic syndrome. Blood 1996, 88:1122-1123.
12. Greenberg P.L. Molecular and genetic features of myelodysplastic syndromes. Int J Lab Hematol 2012, 34:215-222.
13. Greenberg P.L., Young N.S., Gattermann N. Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2002, 13:6-61.
14. Gupta P., Niehans G.A., LeRoy S.C., et al. Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival. Leukemia 1999, 13:44-53.
15. Karlic H., Lohninger A., Laschan C., et al. Downregulation of carnitine acyltransferases and organic cation transporter OCTN2 in mononuclear cells in healthy elderly and patients with myelodysplastic syndromes. J Mol Med 2003, 81:435-442.
16. Ohshima K., Karube K., Shimazaki K., et al. Imbalance between apoptosis and telomerase activity in myelodysplastic syndromes: possible role in ineffective hemopoiesis. Leuk Lymphoma 2003, 44:1339-1346.
17. Shimazaki K., Ohshima K., Suzumiya J., et al. Apoptosis and prognostic factors in myelodysplastic syndromes. Leuk Lymphoma 2002, 43:257-260.
18. Sawanobori M., Yamaguchi S., Hasegawa M., et al. Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes. Leuk Res 2003, 27:583-591.
19. Kitagawa M., Yamaguchi S., Takahashi M., et al. Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia. Leukemia 1998, 12:486-492.
20. Kerbauy D.B., Deeg H.J. Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. Exp Hematol 2007, 35:1739-1746.
21. Bernasconi P. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions - a review. Br J Haematol 2008, 142:695-708.
22. Thaler R., Karlic H., Spitzer S., et al. Extra-cellular matrix suppresses expression of the apoptosis mediator Fas by epigenetic DNA methylation. Apoptosis 2010, 15:728-737.
23. Flores-Figueroa E., Gutierrez-Espindola G., Montesinos J.J., et al. In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome. Leuk Res 2002, 26:677-686.
24. Stirewalt D.L., Mhyre A.J., Marcondes M., et al. Tumour necrosis factor-induced gene expression in human marrow stroma: clues to the pathophysiology of MDS. Br J Haematol 2008, 140:444-453.
25. Pang W.W., Price E.A., Sahoo D., et al. Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age. Proc Natl Acad Sci U S A 2011, 108:20012-20017.
26. Fraga M.F., Agrelo R., Esteller M. Cross-talk between aging and cancer: the epigenetic language. Ann NY Acad Sci 2007, 1100:60-74.
27. Fraga M.F., Esteller M. Epigenetics and aging: the targets and the marks. Trends Genet 2007, 23:413-418.
28. Afanas I. Reactive oxygen species singaling in cancer: comparison with aging. Aging Dis 2011, 2:219-230.
29. Marciniak R., Guarente L. Human genetics. Testing telomerase. Nature 2001, 413:370-371. [373].
30. Rudolph K.L., Chang S., Lee H.W., et al. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 1999, 96:701-712.
31. Kujoth G.C., Hiona A., Pugh T.D., et al. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science 2005, 309:481-484.
32. Zhang C., Liu V.W., Addessi C.L., et al. Differential occurrence of mutations in mitochondrial DNA of human skeletal muscle during aging. Hum Mutat 1998, 11:360-371.
33. Longo V.D., Fabrizio P. Regulation of longevity and stress resistance: a molecular strategy conserved from yeast to humans. Cell Mol Life Sci 2002, 59:903-908.
34. Holzenberger M., Kappeler L., De Magalhaes Filho C. IGF-1 signaling and aging. Exp Gerontol 2004, 39:1761-1764.
35. Razzaque M.S., Lanske B. Hypervitaminosis D and premature aging: lessons learned from Fgf23 and Klotho mutant mice. Trends Mol Med 2006, 12:298-305.
36. Razzaque M.S., Sitara D., Taguchi T., et al. Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process. FASEB J 2006, 20:720-722.
37. Kirkwood T.B. Evolution of ageing. Nature 1977, 270:301-304.
38. Rosenfeld C., List A. A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies. Leukemia 2000, 14:2-8.
39. Agrelo R., Cheng W.H., Setien F., et al. Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc Natl Acad Sci U S A 2006, 103:8822-8827.
40. Capri M., Salvioli S., Sevini F., et al. The genetics of human longevity. Ann NY Acad Sci 2006, 1067:252-263.
41. Cherian S., Bagg A. The genetics of the myelodysplastic syndromes: classical cytogenetics and recent molecular insights. Hematology 2006, 11:1-13.
42. Aoki E., Uchida T., Ohashi H., et al. Methylation status of the p15INK4B gene in hematopoietic progenitors and peripheral blood cells in myelodysplastic syndromes. Leukemia 2000, 14:586-593.
43. Gurkan E., Tanriverdi K., Baslamisli F. Telomerase activity in myelodysplastic syndromes. Leuk Res 2005, 29:1131-1139.
44. Fu C., Chen Z. Telomerase activity in myelodysplastic syndrome. Chin Med J (Engl) 2002, 115:1475-1478.
45. Johnson F.B., Sinclair D.A., Guarente L. Molecular biology of aging. Cell 1999, 96:291-302.
46. Farquhar M.J., Bowen D.T. Oxidative stress and the myelodysplastic syndromes. Int J Hematol 2003, 77:342-350.
47. Mathers J.C. Nutritional modulation of ageing: genomic and epigenetic approaches. Mech Ageing Dev 2006, 127:584-589.
48. Yoshida K., Hirabayashi Y., Watanabe F., et al. Caloric restriction prevents radiation-induced myeloid leukemia in C3H/HeMs mice and inversely increases incidence of tumor-free death: implications in changes in number of hemopoietic progenitor cells. Exp Hematol 2006, 34:274-283.
49. Qi H., Xiao L., Lingyun W., et al. Expression of type 1 insulin-like growth factor receptor in marrow nucleated cells in malignant hematological disorders: correlation with apoptosis. Ann Hematol 2006, 85:95-101.
50. Mellibovsky L., Diez A., Serrano S., et al. Bone remodeling alterations in myelodysplastic syndrome. Bone 1996, 19:401-405.
51. Karlic H., Schuster D., Varga F., et al. Downregulation of collagen, fat-metabolism-markers and telomerase in elderly: an oral mucosa study. Ann Nutr Metab 2007, 51.
52. Koch C.M., Suschek C.V., Lin Q., et al. Specific age-associated DNA methylation changes in human dermal fibroblasts. PLoS ONE 2011, 6:e16679.
53. Wnuk M., Lewinska A., Gurgul A., et al. Changes in DNA methylation patterns and repetitive sequences in blood lymphocytes of aged horses. Age (Dordr) 2013.
54. Fuke C., Shimabukuro M., Petronis A., et al. Age related changes in 5-methylcytosine content in human peripheral leukocytes and placentas: an HPLC-based study. Ann Hum Genet 2004, 68:196-204.
55. Thompson R.F., Atzmon G., Gheorghe C., et al. Tissue-specific dysregulation of DNA methylation in aging. Aging Cell 2010, 9:506-518.
56. So K., Tamura G., Honda T., et al. Quantitative assessment of RUNX3 methylation in neoplastic and non-neoplastic gastric epithelia using a DNA microarray. Pathol Int 2006, 56:571-575.
57. Calvanese V., Lara E., Kahn A., et al. The role of epigenetics in aging and age-related diseases. Ageing Res Rev 2009, 8:268-276.
58. Rodriguez-Paredes M., Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011, 17:330-339.
59. Liu L., van Groen T., Kadish I., et al. Insufficient DNA methylation affects healthy aging and promotes age-related health problems. Clin Epigenet 2011, 2:349-360.
60. Gomes M.V., Toffoli L.V., Arruda D.W., et al. Age-related changes in the global DNA methylation profile of leukocytes are linked to nutrition but are not associated with the MTHFR C677T genotype or to functional capacities. PLoS ONE 2012, 7:e52570.
61. Itoh K., Friel J., Laker C., et al. The role of soluble growth factors in inducing transient growth and clonal extinction of stroma cell dependent erythroblastic leukemia cells. Leukemia 1997, 11:1753-1761.
62. Garrido S.M., Appelbaum F.R., Willman C.L., et al. Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp Hematol 2001, 29:448-457.
63. Del Poeta G., Venditti A., Del Principe M.I., et al. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 2003, 101:2125-2131.
64. Tacke F., Marini F.C., Zhao S., et al. Expression of inducible Bcl-X(S) in myeloid leukemia: compensatory upregulation of Bcl-X(L) and Bcl-2 prevents apoptosis and chemosensitization. Cancer Biol Ther 2004, 3:340-347.
65. Suarez L., Vidriales M.B., Garcia-Larana J., et al. CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes. Clin Cancer Res 2004, 10:7599-7606.
66. Takada Y., Andreeff M., Aggarwal B.B. Indole-3-carbinol suppresses NF-kappaB and IkappaBalpha kinase activation, causing inhibition of expression of NF-kappaB-regulated antiapoptotic and metastatic gene products and enhancement of apoptosis in myeloid and leukemia cells. Blood 2005, 106:641-649.
67. Fabre C., Carvalho G., Tasdemir E., et al. NF-kappaB inhibition sensitizes to starvation-induced cell death in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene 2007, 26:4071-4083.
68. Carvalho G., Fabre C., Braun T., et al. Inhibition of NEMO, the regulatory subunit of the IKK complex, induces apoptosis in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene 2007, 26:2299-2307.
69. Grosjean-Raillard J., Ades L., Boehrer S., et al. Flt3 receptor inhibition reduces constitutive NFkappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia. Apoptosis 2008, 13:1148-1161.
70. Grosjean-Raillard J., Tailler M., Ades L., et al. ATM mediates constitutive NF-kappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene 2009, 28:1099-1109.
71. Jaiswal S., Jamieson C.H., Pang W.W., et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 2009, 138:271-285.
72. Majeti R., Chao M.P., Alizadeh A.A., et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009, 138:286-299.
73. Issa J.P. Epigenetic changes in the myelodysplastic syndrome. Hematol Oncol Clin North Am 2010, 24:317-330.
74. Langer F., Dingemann J., Kreipe H., et al. Up-regulation of DNA methyltransferases DNMT1, 3A, and 3B in myelodysplastic syndrome. Leuk Res 2005, 29:325-329.
75. Li K.K., Luo L.F., Shen Y., et al. DNA methyltransferases in hematologic malignancies. Semin Hematol 2013, 50:48-60.
76. Mizuno S., Chijiwa T., Okamura T., et al. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 2001, 97:1172-1179.
77. Yang B.T., Dayeh T.A., Volkov P.A., et al. Increased DNA methylation and decreased expression of PDX-1 in pancreatic islets from patients with type 2 diabetes. Mol Endocrinol 2012, 26:1203-1212.
78. Jacobsen S.C., Brons C., Bork-Jensen J., et al. Effects of short-term high-fat overfeeding on genome-wide DNA methylation in the skeletal muscle of healthy young men. Diabetologia 2012, 55:3341-3349.
79. Karlic H., Varga F. Epigenetics and tumorigenesis. Epigenetics and Human Health: Linking Hereditary, Environmental and Nutritional Aspects 2009, 179-194. Wiley, Hoboken, NJ. S. Haslberger AGl (Ed.).
80. Wang Y.Y., Cen J.N., He J., et al. Accelerated cellular senescence in myelodysplastic syndrome. Exp Hematol 2009, 37:1310-1317.
81. Sillaber C., Walchshofer S., Mosberger I., et al. Immunophenotypic characterization of human bone marrow endosteal cells. Tissue Antigens 1999, 53:559-568.
82. Zhang J., Cado D., Chen A., et al. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1. Nature 1998, 392:296-300.
83. Michie A.M., McCaig A.M., Nakagawa R., et al. Death-associated protein kinase (DAPK) and signal transduction: regulation in cancer. FEBS J 2010, 277:74-80.
84. Cohen O., Inbal B., Kissil J.L., et al. DAP-kinase participates in TNF-alpha- and Fas-induced apoptosis and its function requires the death domain. J Cell Biol 1999, 146:141-148.
85. Bialik S., Kimchi A. Lethal weapons: DAP-kinase, autophagy and cell death: DAP-kinase regulates autophagy. Curr Opin Cell Biol 2010, 22:199-205.
86. Cohen I., Castedo M., Kroemer G. Tantalizing thanatos: unexpected links in death pathways. Trends Cell Biol 2002, 12:293-295.
87. Raveh T., Droguett G., Horwitz M.S., et al. DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation. Nat Cell Biol 2001, 3:1-7.
88. Raval A., Tanner S.M., Byrd J.C., et al. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell 2007, 129:879-890.
89. Yoo H.J., Byun H.J., Kim B.R., et al. DAPk1 inhibits NF-kappaB activation through TNF-alpha and INF-gamma-induced apoptosis. Cell Signal 2012, 24:1471-1477.
90. Ghanim V., Herrmann H., Heller G., et al. 5-Azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand. Blood 2012, 119:4242-4252.
91. Thaler R., Spitzer S., Karlic H., et al. Ibandronate increases the expression of the pro-apoptotic gene FAS by epigenetic mechanisms in tumor cells. Biochem Pharmacol 2013, 85:173-185.
92. Ettou S., Audureau E., Humbrecht C., et al. Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML. Leukemia 2012, 26:2297-2299.
93. Stankov K., Bogdanovic G., Kojic V., et al. Expression analysis of genes involved in epigenetic regulation and apoptosis in human malignant haematopoietic cell lines treated with 5-azacytidine. J BUON 2011, 16:116-122.
94. Fabiani E., Leone G., Giachelia M., et al. Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. Leuk Lymphoma 2010, 51:2275-2284.
95. Galmarini D., Galmarini C.M., Galmarini F.C. Cancer chemotherapy: a critical analysis of its 60 years of history. Crit Rev Oncol Hematol 2012, 84:181-199.
96. Seymour J.F., Fenaux P., Silverman L.R., et al. Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol 2010, 76:218-227.
97. Gerds A.T., Gooley T.A., Estey E.H., et al. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biol Blood Marrow Transplant 2012, 18:1211-1218.
98. Karlic H., Reitermaier R., Ghanim V., et al. 5-azacytidine and decitabine induce demethylation and re-expression of FAS (CD95) and promote apoptosis in neoplastic cells in acute myeloid leukemia (AML). ASH Annu Meet Abstr 2011, 118:3463.
99. Voso M.T., D'Alo F., Greco M., et al. Epigenetic changes in therapy-related MDS/AML. Chem Biol Interact 2010, 184:46-49.
100. Qian J., Yao D.M., Lin J., et al. Methylation of DAPK1 promoter: frequent but not an adverse prognostic factor in myelodysplastic syndrome. Int J Lab Hematol 2010, 32:74-81.
101. Savickiene J., Treigyte G., Borutinskaite V.V., et al. Antileukemic activity of combined epigenetic agents, DNMT inhibitors zebularine and RG108 with HDAC inhibitors, against promyelocytic leukemia HL-60 cells. Cell Mol Biol Lett 2012, 17:501-525.
102. Savickiene J., Treigyte G., Jonusiene V., et al. Epigenetic changes by zebularine leading to enhanced differentiation of human promyelocytic leukemia NB4 and KG1 cells. Mol Cell Biochem 2012, 359:245-261.
103. Su Y., Xu H., Xu Y., et al. Azacytidine inhibits the proliferation of human promyelocytic leukemia cells (HL60) by demethylation of MGMT, DAPK and p16 genes. Hematology 2012, 17:41-46.
104. Kim K.M., Lee K., Hong Y.S., et al. Fas-mediated apoptosis and expression of related genes in human malignant hematopoietic cells. Exp Mol Med 2000, 32:246-254.
105. Dirks W., Schone S., Uphoff C., et al. Expression and function of CD95 (FAS/APO-1) in leukaemia-lymphoma tumour lines. Br J Haematol 1997, 96:584-593.
106. Haberland M., Montgomery R.L., Olson E.N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009, 10:32-42.
107. Szyf M. DNA methylation and demethylation probed by small molecules. Biochim Biophys Acta 2010, 1799:750-759.
108. Gravina G.L., Festuccia C., Marampon F., et al. Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation. Mol Cancer 2010, 9:305.
109. Du Z., Song J., Wang Y., et al. DNMT1 stability is regulated by proteins coordinating deubiquitination and acetylation-driven ubiquitination. Sci Signal 2010, 3:ra80.
110. Shimazu T., Hirschey M.D., Newman J., et al. Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 2013, 339:211-214.
111. Katada S., Imhof A., Sassone-Corsi P. Connecting threads: epigenetics and metabolism. Cell 2012, 148:24-28.
112. Karlic H., Thaler R., Varga J., et al. Effects of Epigenetic Drugs (Vorinostat, Decitabine) on Metabolism-Related Pathway Factors in Leukemic Cells. Open Leukemia J 2010, 3:34-42.
113. Nitert M.D., Dayeh T., Volkov P., et al. Impact of an exercise intervention on DNA methylation in skeletal muscle from first-degree relatives of patients with type 2 diabetes. Diabetes 2012, 61:3322-3332.
114. Alibhai S.M., O'Neill S., Fisher-Schlombs K., et al. A clinical trial of supervised exercise for adult inpatients with acute myeloid leukemia (AML) undergoing induction chemotherapy. Leuk Res 2012, 36:1255-1261.
115. Fang M.Z., Wang Y., Ai N., et al. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 2003, 63:7563-7570.
116. Stefanska B., Karlic H., Varga F., et al. Epigenetic mechanisms in anti-cancer actions of bioactive food components - the implications in cancer prevention. Br J Pharmacol 2012, 167:279-297.
117. Cui X., Wakai T., Shirai Y., et al. Arsenic trioxide inhibits DNA methyltransferase and restores methylation-silenced genes in human liver cancer cells. Hum Pathol 2006, 37:298-311.
118. Garcia-Manero G. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012, 87:692-701.
119. Schanz J., Tuchler H., Sole F., et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS Derived from an international database merge. J Clin Oncol 2012, 30:820-829.
120. Gadji M., Adebayo Awe J., Rodrigues P., et al. Profiling three-dimensional nuclear telomeric architecture of myelodysplastic syndromes and acute myeloid leukemia defines patient subgroups. Clin Cancer Res 2012, 18:3293-3304.
121. Westman M.K., Pedersen-Bjergaard J., Andersen M.T., et al. IDH1 and IDH2 mutations in therapy-related myelodysplastic syndrome and acute myeloid leukemia are associated with a normal karyotype and with der(1;7)(q10;p10). Leukemia 2013, 27:957-959.
122. Krall A.S., Christofk H.R. Cancer: a metabolic metamorphosis. Nature 2013, 496:38-40.
123. Losman J.A., Looper R.E., Koivunen P., et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 2013, 339:1621-1625.
124. Shih A.H., Abdel-Wahab O., Patel J.P., et al. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 2012, 12:599-612.
125. Erdogan B., Bosompem A., Peng D., et al. Methylation of promoters of microRNAs and their host genes in myelodysplastic syndromes. Leuk Lymphoma 2013, [Epub ahead of print].
126. Nagata S., Golstein P. The Fas death factor. Science 1995, 267:1449-1456.
127. Ettou S., Humbrecht C., Benet B., et al. FAS gene expression is epigenetically regulated and predicts the responsiveness to azacitidine in high-risk myelodysplastic syndromes. Blood 2010, 116. [Abstract 232].
128. Parker J.E., Mufti G.J., Rasool F., et al. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000, 96:3932-3938.
129. Wu X., Liu W., Tian Y., et al. Aberrant methylation of death-associated protein kinase 1 CpG islands in myelodysplastic syndromes. Acta Haematol 2011, 125:179-185.
130. Hess C.J., Errami A., Berkhof J., et al. Concurrent methylation of promoters from tumor associated genes predicts outcome in acute myeloid leukemia. Leuk Lymphoma 2008, 49:1132-1141.
131. Valent P., Bonnet D., De Maria R., et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer 2012, 12:767-775.
132. Claus R., Hackanson B., Poetsch A.R., et al. Quantitative analyses of DAPK1 methylation in AML and MDS. Int J Cancer 2012, 131:E138-E142.
133. Fandy T.E., Herman J.G., Kerns P., et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009, 114:2764-2773.
134. Itzykson R., Fenaux P. Optimizing hypomethylating agents in myelodysplastic syndromes. Curr Opin Hematol 2012, 19:65-70.
135. Scott S.A., Lakshimikuttysamma A., Sheridan D.P., et al. Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression. Exp Hematol 2007, 35:263-273.
136. Dodge J.E., Munson C., List A.F. KG-1 and KG-1a model the p15 CpG island methylation observed in acute myeloid leukemia patients. Leuk Res 2001, 25:917-925.
137. Watson C.J., O'Kane H., Maxwell P., et al. Identification of a methylation hotspot in the death receptor Fas/CD95 in bladder cancer. Int J Oncol 2012, 40:645-654.
138. Jones C.L., Wain E.M., Chu C.C., et al. Downregulation of Fas gene expression in Sezary syndrome is associated with promoter hypermethylation. J Invest Dermatol 2010, 130:1116-1125.
139. Varga F., Karlic H., Thaler R., et al. Functional aspects of cytidine-guanosine dinucleotides and their locations in genes. Biomol Concepts 2011, 2:391-405.
140. Bos J.L., Verlaan-de Vries M., Jansen A.M., et al. Three different mutations in codon 61 of the human N-ras gene detected by synthetic oligonucleotide hybridization. Nucleic Acids Res 1984, 12:9155-9163.
141. Schepers H., Wierenga A.T., Eggen B.J., et al. Oncogenic Ras blocks transforming growth factor-beta-induced cell-cycle arrest by degradation of p27 through a MEK/Erk/SKP2-dependent pathway. Exp Hematol 2005, 33:747-757.
142. Lubbert M., Jonas D., Miller C.W., et al. Retrospective analysis of ras gene activation in myeloid leukemic cells. Oncogene 1990, 5:583-587.
143. Zeng L., Li T., Xu D.C., et al. Death receptor 6 induces apoptosis not through type I or type II pathways, but via a unique mitochondria-dependent pathway by interacting with Bax protein. J Biol Chem 2012, 287:29125-29133.
144. Lamkanfi M., Kanneganti T.D. Caspase-7: a protease involved in apoptosis and inflammation. Int J Biochem Cell Biol 2010, 42:21-24.
145. Kuribayashi K., Mayes P.A., El-Deiry W.S. What are caspases 3 and 7 doing upstream of the mitochondria?. Cancer Biol Ther 2006, 5:763-765.
146. Moruno-Manchon J.F., Perez-Jimenez E., Knecht E. Glucose induces autophagy under starvation conditions by a p38 MAPK-dependent pathway. Biochem J 2013, 449:497-506.
147. Distelhorst C. Autophagy and metabolism in lymphoid malignancies. Blood (ASH Annu Meet Abstr) 2011, 118. [Abstract 26].
148. Orfali N., Bao M., O'Donovan T., et al. Autophagy as a target for differentiation therapy in acute myeloid leukemia. Blood (ASH Annu Meet Abstr) 2012, 120. [Abstract 2464].
149. Rothe K., Lin K., Lin H., et al. identification of a unique autophagy gene expression signature in CD324+ CML stem/progenitor cells that correlates with clinical response to imatinib mesylate. Blood (ASH Annu Meet Abstr) 2012, 120. [Abstract 1662].
150. Maecker H.L., Yun Z., Maecker H.T., et al. Epigenetic changes in tumor Fas levels determine immune escape and response to therapy. Cancer Cell 2002, 2:139-148.
151. Shimizu M., Yoshimoto T., Sato M., et al. Frequency and resistance of CD95 (Fas/Apo-1) gene-transfected tumor cells to CD95-mediated apoptosis by the elimination and methylation of integrated DNA. Int J Cancer 2006, 119:585-592.
152. Banerji V., Gibson S.B. Targeting metabolism and autophagy in the context of haematologic malignancies. Int J Cell Biol 2012, 2012:595976.
153. Li L., Ishdorj G., Gibson S.B. Reactive oxygen species regulation of autophagy in cancer: implications for cancer treatment. Free Radic Biol Med 2012, 53:1399-1410.
154. Ishdorj G., Li L., Gibson S.B. Regulation of autophagy in hematological malignancies: role of reactive oxygen species. Leuk Lymphoma 2012, 53:26-33.
155. Oki Y., Issa J.P. Epigenetic mechanisms in AML - a target for therapy. Cancer Treat Res 2010, 145:19-40.